+ Watch SHPG
on My Watchlist
A pharmaceutical company that focuses on meeting the needs of the specialist physician.
Monopoly on the ADHD drugs until the Vyvanse patents expire or something better comes out before then.
great buy-in point
I like their focus on rare diseases. That sets them apart from the competition.
SHPG growth rate yr over yr 26.67% 1 yr growth rate 9.80% eps -13.80% div 0.53trailing 12Q rev 3.67 B eps 3.28 ytd div 0.531yr change +55.22%net change in cash & cash equivalents 862.20
Continuing gastro and ADD/ADHD pipeline
Overall a great company
Investors.com 99 Composite Rating
Going to be bought by a large company
As Genzyme continues to suffer with FDA and EU concerns, Shire is swooping in and displacing a captive market. This company is amping up a significant manufacturing base and jumping at the opportunity to gill Genzyme's market.
If they get the nod from FDA, this stock will take-off. With GENZ dealing with manufacturing issues, SHPGY can take on some market share with their new drug in the same category.
This stock should out perform in the next few months due the shut down and production stop forced by the FDA on Genezyme and Shire is the only other manufacture that is getting back flow to fill orders.
Still looks overpriced. Trying to get patients to switch to Vyvanse will be difficult with generic Adderall available.
Possible buyout by PFE
A rise in Vyvanse market share will drive the value up. Potential takeover.
Vyvanse, their new drug for ADHD, will likely get an Adult indication from the FDA within 4-6 months, and its 12 hour duration on one pill a day is a real improvement in this area
New longer lasting ADD/ADHD drug (Vyvanse) with FDA approval entering the market. While Adderall may be generic soon, Vyvanse is a once per day dosing as apposed to typically twice per day with Adderall XR.Also, Shire's HGT (Human Genetic Therapy) division is the exclusive supplier of therapies for some genetic conditions (such as Hunter's Syndrome). Pipeline seems to be undervalued as well.
more than fair value. will normalize soon.
Easy double on massive near-term growth. Market is slow to catch on, and this stock is grossly undervalued.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions